Clinical Trials

Clinical Trial Detail

Return to search results.

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Complete title: Phase 2 Study of SPI-1620 in Combination with Docetaxel as a Second-Line Treatment for Patients with Advanced Biliary Cancer

Research Study Number       20131451
Principal Investigator       Gabriela Chiorean
Phase       II

Look up trial at NIH

Research Study Description

The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.

Eligibility Criteria (must meet the following to participate in this study)

- * For Eligibility information, please click on the "Look up trial at NIH" link above.

Other eligibility criteria may apply.

Research Study Number       20131451
Contact       Seattle Cancer Care Alliance Intake Office
Telephone       800-804-8824 / 206-288-1024

Bile Duct Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials